Navigation Links
Rural/Metro Announces Results for Fiscal 2008 First Quarter; Fiscal 2007 Fourth Quarter and Full Year
Date:11/14/2007

(131) (108) (1,389) (759)

Income (loss) from continuing

operations (1,119) 2,294 (1,276) 8,827

Income (loss) from discontinued

operations, net of income taxes (57) (1,241) 267 (5,947)

Net income (loss) $(1,176) $1,053 $(1,009) $2,880

Income (loss) per share:

Basic -

Income (loss) from continuing

operations $(0.05) $0.09 $(0.05) $0.36

Income (loss) from

discontinued operations (0.00) (0.05) 0.01 (0.24)

Net income (loss) $(0.05) $0.04 $(0.04) $0.12

Diluted -

Income (loss) from continuing

operations $(0.05) $0.09 $(0.05) $0.36

Income (loss) from

discontinued operations (0.00) (0.05) 0.01 (0.24)

Net income (loss) $(0.05) $0.04 $(0.04) $0.12

Average number of common shares

outstanding - Basic 24,695 24,468 24,604 24,359

Average number of common shares

outstanding - Diluted 24,695 24,910 24,604 24,842

RURAL/METRO CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

Fiscal Year Ended June 30,

2006

2007 (As restated)

Cash flows from operating activities:

Net income (loss) $(1,009) $2,880

Adjustments to reconcile net income to

net cash provided by operating

activities -

Depreciation and amortization 12,132 11,351


'/>"/>

SOURCE Rural/Metro Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. Rural/Metro Board of Directors Meets With Accipiter Capital Management
2. Rural/Metro Enters Into Amendment and Waiver to Its Senior Credit Facility; Provides Restatement Details
3. Rural/Metro to Host Conference Call to Discuss Results for First Quarter Fiscal 2008 and Fourth Quarter/Fiscal 2007 Year-End
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)... , Brain perfusion applic...nterprise using the Ziostation® thin-client sy...if (PRWEB) January 8, 2009 -- Ziosoft®, Inc. ...software for medical imaging , today announced th...Food and Drug Administration (FDA) for its CT brai...
(Date:1/7/2009)... , SEATTLE, Jan. 8 Ce... announced today that they received $7.5 million p...trum Pharmaceuticals, Inc. to commercialize and de..., the Company received the initial $7.5 million pa...action. The Company may earn up to an additional ...
(Date:1/7/2009)... , BOSTON The drive toward containing health ca...reducing physician productivity, impairing quality...l Deaconess Medical Center physicians suggest in a..., Citing studies in behavioral economics and psyc...D, express the fear that assigning a monetary valu...
(Date:1/7/2009)... , SAN MARCOS, Calif., Jan, 7 Natural Alternative... leading formulator, manufacturer and marketer of ...d that effective December 31, 2008 its former Pres... , , NAI also announced it completed certain amen...k. Among other changes the amendments extend the ...
Breaking Medicine News(10 mins):Health News:Ziosoft Receives FDA Clearance for CT Brain Perfusion Application 2Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 2Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 3Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 4Health News:Cost containment focus could have consequences for health care delivery 2Health News:Natural Alternatives International, Inc. Announces Change in Executive Officer and Loan Modification and Extension 2
...high cholesterol levels are more likely to develop.... Researchers studied the eating habits and choles...about five years. The children were examined by do...ol, and LDL, or bad cholesterol, measured periodic...
...e that male babies who grow slowly in their first ... results hold true regardless of the socioeconomic...w infant growth may be accompanied by hampered bra...oor growth in infancy lead to lifelong impairment ...
...solved the puzzle of why baby boys are so much big...ring pregnancy. Women carrying male embryos consum...re protein and have a higher intake of carbohydrat...cepted that on average newborn boys are heavier th...
... the frequency of hot flashes in menopausal women,...gh an independent researcher said the drug's effec...rmone replacement therapy for menopausal symptoms ...sleep problems will be looked at more closely beca...
Other Medicine News:
(Date:1/7/2009)...RNewswire/ -- Circassia Ltd, a specialty,biopharm...care, today,announced that following successful c...une(R) anti-allergy technology, the company has no...se II clinical trial in cat allergy. The,study, w...ents with confirmed,cat allergies, and all the pa...
(Date:1/6/2009)...e-USNewswire/ -- Sequella, Inc., a clinical-stage ...pidemic potential, announced today that SQ109, its...osis (TB), was the first drug approved for evaluat...o Dynport Vaccine Company LLC and Quintiles Transn...titute of Allergy and Infectious Diseases (NIAID),...
(Date:1/5/2009)...wire-FirstCall/ -- Micromet, Inc.,(Nasdaq: MITI...proprietary,antibodies for the treatment of cance... an outlook on key events anticipated for the year...pdate on its research and development,programs at... 2009: Update on several preclinical BiTE antibodi...
(Date:12/27/2008)...Newswire-FirstCall/ -- Warner Chilcott Limited (Na...sidiaries and Mayne Pharma International Pty. Ltd....led lawsuits against each of Mutual Pharmaceutical...nc. ("Mylan") and Impax Laboratories, Inc. ("Impax...Jersey for infringement of Mayne,s U.S. Patent No....
Breaking Medicine Technology:Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 1UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 2UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 3UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 4UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 5LA BioMed researcher says unexpected increase in cancer risk found 13475 1LA BioMed researcher says unexpected increase in cancer risk found 13475 2LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 1LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 2LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 3LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 4LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 5LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 6LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 7LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 8LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 9LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 10LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 11LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 12Bristol Myers Squibb Announces Dividend 3710 1
...erland, April 25, 2007 - Basilea Pharmaceutica Ltd...s showing that,patients with severe chronic hand e...oin. In two previous randomized clinical,trials, a...severe,chronic hand eczema in patients refractory ...ated that patients responsive to initial,treatment...
....--(BUSINESS WIRE)--Apr 25, 2007 - OSI,Pharmaceuti...ults,published yesterday in the Journal of Clinica... to gemcitabine chemotherapy,significantly improve... to patients with advanced pancreatic cancer. Data... Institute of Canada (NCIC),formed the basis of b...
Other Medicine Technology:Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 2Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 3Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 4Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 5OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 2OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 3OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 4
STABIBAG Hydrophilic Acrylic Lens.
XL STABI Hydrophilic Acrylic Lens.
FZ60 : the 1st monobloc hard & soft IOL. Thanks to an exclusive and patented process : the selective polymerisation, IOLTECH designed the first single piece rigid & soft IOL : the FZ60. This technolo
XL OCTO Hydrophilic Acrylic Lens.
Medicine Products: